BioSpace News Archive

Maternal Fetal Medicine Associates is excited to announce an expansion into the field of gynecological services for women in the New York City area.

BioCelerate, a subsidiary of TransCelerate BioPharma Inc., today announced a collaboration with the Food and Drug Administration (FDA) to launch a joint working group which will explore methods to enable more effective analysis of nonclinical studies across the research community.

The American Conservative’s 3rd Annual Crony Capitalism Conference Wednesday June 12, 8:30 a.m. to 11 a.m. The National Press Club, Holeman Lounge, 529 14th St. NW, Washington

The CSU Institute for Palliative Care is now the Shiley CSU Institute for Palliative Care, thanks to another generous gift from prominent local philanthropist Darlene Marcos Shiley.

This weekend, Dreem announced an innovative program for sleep researchers at SLEEP 2019, the 33rd annual meeting of the APSS, a joint meeting held by the American Academy of Sleep Medicine and the Sleep Research Society.

New Rhein Healthcare Investors, a Philadelphia based private equity manager focused on healthcare therapeutics and medical devices, held its inaugural Industry Day on June 2nd at the Rittenhouse Hotel in advance of the International BIO Conference held this year in Philadelphia.

OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, will host its latest State of the Science Summit™ on non-small cell lung cancer on Monday, June 17, from 5 to 9 p.m. at the Boston Marriott Newton in Newton, Massachusetts.

Wolf & Company P.C. is pleased to announce that Renee Broadbent has joined the firm, working with clients in the healthcare industry on improving their information security practices and compliance

Enzo Biochem, Inc. (NYSE:ENZ), an integrated life sciences company focused on commercializing innovative diagnostic and therapeutics products, today reported results for the fiscal quarter and nine months ended April 30, 2019.

On June 7, 2019, the Federal Food and Drug Administration (FDA) issued a public statement related to proper use of bulk ingredients, specifically for compounded sterile injectable dosage forms.